Search Immortality Topics:

Page 10,189«..1020..10,18810,18910,19010,191..10,20010,210..»

An Horse “Postcards”

Posted: May 27, 2010 at 8:17 am

An Horse does it again with their with their “Postcards” music video from their debut album “Rearrange Beds.”

Directed by Celeste Potter and David Rusanow.  They mounted a camera on the ceiling and took a picture every five seconds for the five and half hours it took to complete the anatomical man.  It’s mesmerizing watching them create this sad little guy.

The video was inspired by an animated sketch Celeste did of which she simply said, “I think I will make a whole video like this.” Click here to see the animation.

[spotted by Alex]

Recommendation and review posted by G. Smith

Regernative Medicine Podcast #81

Posted: May 27, 2010 at 8:16 am

Listen to show #81 here!
RegenMedToday_81_April2010.mp3 [11.0MB 00:28:22 80kbps]

Regenerative Medicine Today welcomes Sam Rothstein. Mr. Rothstein is a chemical engineering predoctoral fellow in the lab of Dr. Steven Little. He discusses the lab?s research on the mechanics of controlled release and mathematical model-driven methodology. He also discusses his plans for a new drug formulation company, ChroKnow Solutions.

For more information about the Little Lab, please Click Here.

For more information about the McGowan Institute for Regenerative Medicine, visit: McGowan Institute Research Site

McGowan Institute Patient Site

Host John Murphy Subscribe to the Podcast Feed.

Recommendation and review posted by G. Smith

Regernative Medicine Podcast #80

Posted: May 27, 2010 at 8:16 am

Listen to show #80 here!
RegenMedToday_080_March2010.mp3 [11.0MB 00:28:22 80kbps]

Regenerative Medicine Today welcomes Gregory Schultz, PhD. Dr. Schultz is Professor of Obstretrics and Gynecology in the Department of Biochemistry and Molecular Biology, University of Florida. Dr. Schultz discusses his research on wound healing and the challenges presented by bacterial biofilms. He also explains his current joint study, which evaluates bioburden and potential healing markers in chronic wounds. For more information about Dr. Gregory Schultz, please Click Here.

For more information about HEALTHPOINT, Ltd, please Click Here.

Recommendation and review posted by G. Smith

Regernative Medicine Podcast #79

Posted: May 27, 2010 at 8:16 am

Listen to show #79 here!
RegenMedToday_079_Feb2010.mp3 [11.0MB 00:28:22 80kbps]

Regenerative Medicine Today welcomes Johnny Huard, PhD. Dr. Huard is the Henry J. Mankin Endowed Chair in Orthopaedic Surgery Research, the director of the Stem Cell Research Center, and the deputy director for cellular therapy at the McGowan Institute for Regenerative Medicine. Dr. Huard discusses adult stem cell research and the potential it has to provide future treatments for damaged or diseased tissues. He also reviews his research that is now matured to the point that clinical studies are underway.

For more information about Dr. Huard, please Click Here.

For more information about the Stem Cell Research Lab, please Click Here.

For more information about Cook Myocite, Inc., please Click Here.

For more information about the McGowan Institute for Regenerative Medicine, visit:

McGowan Institute Patient Site

McGowan Institute Research Site

Host John Murphy.

Subscribe to the Podcast Feed.

Recommendation and review posted by G. Smith

Breaking 23andMe’s Terms of Service: Not just the patient’s problem.

Posted: May 27, 2010 at 8:16 am

A blogger over at 5Am Solutions Blog is about to break 23andMe's Terms of Service.

"So I called my primary care physician's office and told the appointment-taker I wanted to discuss my 23andMe results with my doctor. She said 'ok' and scheduled an appointment for next week."

May I just add. It is not the doctor breaking the Terms of Service here. It is the customer by bringing it in to their doctor.

"BOOM! That patient coerced that doctor into malpractice liability.Section 3 of 23andMe Terms of Service: “The Services Content is not to be used, and is not intended to be used, by you or any other person to diagnose, cure, treat, mitigate, or prevent a disease or other impairment or condition, or to ascertain your health.”

The worst of this is that 23andMe ACTIVELY INSTRUCTS its users to violate this clause —not only personally, but to also implicate their medical doctors in crime.

And the doctor is trapped: he can respect the law and alienate the patient, or ignore the law and appease the patient."

Oh, wait. Maybe by using 23andMe I am now involved in their legal mess? Crap!

That being said, I just received the Counsyl results from one of my patients yesterday. Unlike being put in a risky position by the good folks at 23andMe, Counsyl is straight up clinical and useful.

I will be notifying the patient via secure email of his results and spending an hour going over it with him.

The Sherpa Says: 23andMe, just like others in the space have demonstrated a general disrespect of the precarious position they have put physicians in by using such crazy and convoluted Terms of Service to avoid regulations. But heck, why should they care about the hot water they put us in.

Recommendation and review posted by G. Smith

International Stem Cell Corporation Moves International Cornea Development Program Forward

Posted: May 26, 2010 at 8:16 am

International Stem Cell Corporation (OTCBB:ISCO),, today announced significant progress on its international development strategy for stem cell-derived human corneal tissue. Such tissue can potentially be used to replace cadaver-derived corneas in treatment of severe corneal vision impairment and to eliminate the need to use live animals in safety testing of drugs, chemicals and consumer products.

During a recent trip to Asia and Europe, an ISCO senior management team identified and interacted with a group of integrated eye hospitals and ophthalmology research institutions with world-class laboratory facilities, along with potential sources of research funding. One of these is Sankara Nethralaya (, one of India's leading not-for-profit clinical and research organizations dedicated to treatment of eye diseases.

Research during the past ten to fifteen years has demonstrated stem cell differentiation into a variety of human cell types. Rarely has it been possible to produce such integrated, functional human tissue, in this case, tissue that has characteristics compatible with human cornea in structure and function. This tissue technology may offer a first-in-class opportunity for high-quality, cost-efficient transplantation tissue for the 10 million people world-wide suffering from corneal vision impairment, particularly in Asia and Europe. It may also provide a much needed alternative to the use of live and extracted animal eyes in the $500+M market for safety testing of drugs, chemicals and consumer products.

During the coming months, ISCO expects to formalize relationships with a number of entities such as Sankara Nethralaya to provide ISCO's cornea development program with the scientific, facility and financial resources needed to advance the technology as rapidly as possible to clinical application. The ultimate goal is not only to address the clear unmet medical and safety testing needs, but also to be among the first pluripotent stem cell applications to achieve widespread commercialization.

Dr. Sengamedu Srinivasa Badrinath, President and Chairman Emeritus of Sankara Nethralaya says: 'At Sankara Nethralaya, we see 1,600 eye patients and do over 100 eye surgeries a day. We employ sixty scientists and clinicians dedicated to the development and application of new state-of-the-art ophthalmic technologies. My senior team at Sankara Nethralaya and I look forward to helping ISCO advance its cornea technology that has potential to significantly reduce the severe quantitative and qualitative limitations in corneal donor tissue across the world today.'

Brian Lundstrom, ISCO's President, continues: 'The addition of Sankara Nethralaya to our international collaborative network will contribute substantial scientific and clinical ophthalmology expertise and resources and complement the instrumentation alliance with The Automation Partnership and the safety testing collaboration with Absorptions Systems. The next step is to organize an experienced therapeutic development team to establish the optimal development path with relevant regulatory authorities and create data needed to advance ISCO's stem cell-derived corneal tissue into clinical trials.'

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human parthenogenetic stem cells (hpSCs) from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website,

To subscribe to receive ongoing corporate communications please click on the following link:

Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Brian Lundstrom, President

Recommendation and review posted by Fredricko

Page 10,189«..1020..10,18810,18910,19010,191..10,20010,210..»